港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,793.042

+20.8101.17%

涨家数：4

跌家数：4

平家数：- -

市盈率：- -

高：1,835.570

开：1,770.415

低：1,747.549

收：1,772.232

数据加载中...

药明康德2月27日现1笔大宗交易成交金额201.71万元

新浪证券-红岸工作室

恒瑞医药(600276.SH)：注射用SHR-A2009、阿得贝利单抗注射液获得药物临床试验批准

复星医药获批XS-03片临床试验

康龙化成2月27日现1笔大宗交易成交金额1116.8万元

新浪证券-红岸工作室

【复星医药：控股子公司XS-03片相关治疗方案获临床试验批准】金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。

金斯瑞生物科技02月27日遭主力抛售1974万元

阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极

金斯瑞生物科技盘中异动下午盘急速跳水5.01%报12.880港元

药明生物再次通过日本PMDA GMP检查累计通过42次全球药品监管机构检查

药明康德盘中异动早盘股价大跌3.00%报61.400港元

艾美疫苗获FDA批准开展mRNA疫苗临床试验

昭衍新药盘中异动早盘股价大涨5.37%

维亚生物盘中异动大幅拉升5.04%报1.460港元

三重buff叠加，医疗ETF（512170）尾盘溢价飙升！CXO强劲反弹，药明康德涨超3%！AI医疗再调整，迪安诊断领跌

康龙化成2月26日现1笔大宗交易成交金额1123.2万元

新浪证券-红岸工作室

恒瑞医药(600276.SH)：HRS-1301片获得药物临床试验批准

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=9"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1793.0419,"timestamp":1741334919514,"preClose":1772.232,"halted":0,"volume":105965997,"delay":0,"changeRate":0.011742,"change":20.809814,"pbRate":2.65369,"amount":2334342230,"amplitude":0.049667,"prevYearClose":1395.7731,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"turnoverRate":0.008873,"marketCap":381645564416,"floatMarketCap":165840598400,"peRate":33.079805},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1835.5696,"amplitude":0.049667,"preClose":1772.232,"low":1747.5487,"pbRate":"2.65369","latestPrice":1793.0419,"volume":105965997,"delay":0,"open":1770.415,"prevYearClose":1395.7731,"prevWeekClose":1793.042,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1699.456,"twentyDayClose":1588.191,"sixtyDayClose":1337.64,"secType":"PLATE","market":"HK","turnoverRate":0.008873,"peRate":33.079805,"marketCap":381645564416,"floatMarketCap":165840598400,"timestamp":1741334919514,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":4,"down":4,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514879090","title":"药明康德2月27日现1笔大宗交易 成交金额201.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514879090","media":"新浪证券-红岸工作室","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514879090?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:40","pubTimestamp":1740649200,"startTime":"0","endTime":"0","summary":"　　2月27日，药明康德收跌3.07%，收盘价为62.45元，发生1笔大宗交易，合计成交量3.23万股，成交金额201.71万元。　　第1笔成交价格为62.45元，成交3.23万股，成交金额201.71万元，溢价率为0.00%，买方营业部为华泰证券股份有限公司总部，卖方营业部为中信证券股份有限公司上海分公司。　　进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为1.22亿元。该股近5个交易日累计下跌2.97%，主力资金合计净流出10.28亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-27/doc-inemxmap0862580.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0708995583.HKD","LU1997245094.SGD","BK1583","LU2125910500.SGD","LU2488822045.USD","LU0456842615.SGD","LU2045819591.USD","LU0052750758.USD","LU0320764599.SGD","02359","LU1997245177.USD","LU2242644610.SGD","603259","BK1576","BK0216","LU1046422090.SGD","BK1141"],"gpt_icon":0},{"id":"2514873549","title":"恒瑞医药(600276.SH)：注射用SHR-A2009、阿得贝利单抗注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514873549","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514873549?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:21","pubTimestamp":1740648081,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-A2009、阿得贝利单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。截至目前，阿得贝利单抗注射液相关项目累计研发投入约78,471万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","600276","BK1583","LU2148510915.USD","BK0196","LU1064131003.USD","BK0183","BK0060","LU0405327494.USD","BK0012","BK0028","LU0405327148.USD","LU1969619763.USD","LU1064130708.USD","BK0188","BK0239","BK1576","BK1141","LU2488822045.USD","03347","LU1328615791.USD"],"gpt_icon":0},{"id":"2514216820","title":"复星医药获批XS-03片临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514216820","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514216820?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:01","pubTimestamp":1740646881,"startTime":"0","endTime":"0","summary":"2月27日，复星医药发布公告，控股子公司星盛新辉近日获得国家药品监督管理局批准，进行XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验。XS-03为公司自主研发的小分子口服PLK1抑制剂，具有抑制肿瘤细胞增殖及促进肿瘤细胞凋亡的作用。公告指出，全球范围内尚无同靶点的小分子抑制剂获批上市，这为XS-03的临床试验提供了市场机会。2024年前三季度，复星医药实现收入309.12亿元，归母净利润20.11亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271703389894b086&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1593","BK1191","BK1515","02196","BK1576","BK1583","03347","600196"],"gpt_icon":0},{"id":"2514875396","title":"康龙化成2月27日现1笔大宗交易 成交金额1116.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514875396","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514875396?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 17:01","pubTimestamp":1740646860,"startTime":"0","endTime":"0","summary":"　　2月27日，康龙化成收跌0.57%，收盘价为28.10元，发生1笔大宗交易，合计成交量40万股，成交金额1116.8万元。　　第1笔成交价格为27.92元，成交40.00万股，成交金额1,116.80万元，溢价率为-0.64%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生14笔大宗交易，合计成交金额为2.07亿元。该股近5个交易日累计下跌1.44%，主力资金合计净流出6192.99万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-27/doc-inemxmap0845095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["03759","BK0216","BK1141","BK1576","300759"],"gpt_icon":0},{"id":"2514891820","title":"【复星医药：控股子公司XS-03片相关治疗方案获临床试验批准】金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891820","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891820?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 16:54","pubTimestamp":1740646452,"startTime":"0","endTime":"0","summary":"金融界2月27日消息，复星医药控股子公司江苏星盛新辉医药有限公司的XS-03片与FOLFOX或FOLFIRI和贝伐珠单抗联合用于治疗RAS突变转移性结直肠癌的临床试验获批准。XS-03是自主研发的小分子口服PLK1抑制剂，在多种肿瘤模型中展现显著药效且临床安全性良好，现阶段针对该方案累计研发投入约20万元。全球范围内尚无同靶点的小分子抑制剂单药或联合治疗方案获批上市。但该方案及XS-03尚需开展系列临床研究并经审批通过方可上市，新药研发存在风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/27165448428408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0188","BK0096","BK1576","BK1515","BK0028","BK0183","03347","BK1574","BK0196","BK0060","159938","02196","600196","BK1583","09939","BK0175","BK1161","BK1593","BK0012","BK0187","BK1191","BK0239","BK1141"],"gpt_icon":0},{"id":"2514733908","title":"金斯瑞生物科技02月27日遭主力抛售1974万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514733908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514733908?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 16:16","pubTimestamp":1740644186,"startTime":"0","endTime":"0","summary":"02月27日, 金斯瑞生物科技股价跌2.21%，报收13.26元，成交金额3.61亿元，换手率1.28%，振幅7.08%，量比1.01。金斯瑞生物科技今日主力资金净流出1974万元，上一交易日主力净流出150万元。该股近5个交易日上涨7.41%，主力资金累计净流出1211万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入6464万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171056abdf0aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227171056abdf0aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","01548","HK0000320264.USD","BK1583","HK0000306685.HKD","HK0000306701.USD","BK1141","HK0000320223.HKD"],"gpt_icon":0},{"id":"2514593844","title":"阿斯利康(AZN.US)口服小分子疗法3期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2514593844","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514593844?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 14:01","pubTimestamp":1740636060,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月27日，阿斯利康宣布，3期临床试验SERENA-6的中期分析显示，其在研口服选择性雌激素受体降解剂camizestrant与CDK4/6抑制剂联用，在主要终点无进展生存期上显示出统计学显著且具有临床意义的改善。据了解，SERENA-6是首个采用循环肿瘤DNA检测，发现肿瘤内分泌耐药性的出现并在疾病进展前提示治疗转换的全球性3期临床试验。Camizestrant是一种效力强劲的新一代口服SERD及雌激素受体完全拮抗剂，目前正在3期试验中接受评估，用于治疗HR阳性乳腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1255131.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0109394709.USD","LU0320765992.SGD","LU2456880835.USD","BK4007","BK4585","LU0889565916.HKD","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","BK1141","BK4588","BK1576","BK4568","03347","LU2417539215.USD","AZN","BK1583"],"gpt_icon":0},{"id":"2514846073","title":"金斯瑞生物科技盘中异动 下午盘急速跳水5.01%报12.880港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846073","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846073?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 13:01","pubTimestamp":1740632476,"startTime":"0","endTime":"0","summary":"2025年02月27日下午盘13时01分，金斯瑞生物科技股票出现异动，股价快速下跌5.01%。截至发稿，该股报12.880港元/股，成交量1731.5万股，换手率0.81%，振幅6.49%。资金方面，该股资金流入6511.4万港元，流出1.25466亿港元。金斯瑞生物科技股票所在的生物技术行业中，整体跌幅为1.65%。金斯瑞生物科技公司简介：金斯瑞生物科技股份有限公司是一家主要从事生物科学研究及相关业务的香港投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227130117a255c486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227130117a255c486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","HK0000320223.HKD","HK0000306685.HKD","BK1576","HK0000306701.USD","01548","HK0000320264.USD","BK1583"],"gpt_icon":0},{"id":"2514849719","title":"药明生物再次通过日本PMDA GMP检查 累计通过42次全球药品监管机构检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2514849719","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514849719?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 12:30","pubTimestamp":1740630600,"startTime":"0","endTime":"0","summary":"无锡2025年2月27日 /美通社/ --全球领先的合同研究、开发和生产服务公司药明生物宣布，公司无锡基地的生物药原液生产厂再次通过日本药品医疗器械综合机构GMP检查。公司以零缺陷通过此次涵盖设施质量体系及生产全流程的现场检查，彰显了其在满足全球监管要求方面的卓越能力。截至目前，药明生物已累计成功通过42次全球药品监管机构检查，并获得美国、欧洲、中国、新加坡、日本及加拿大等国家和地区药监部门颁发的97项生产许可证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4628886_ZH28886_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1794554557.SGD","LU0043850808.USD","LU0348825331.USD","LU1880383366.USD","LU1242518857.USD","LU0051755006.USD","BK1589","LU0516423091.SGD","LU0140636845.USD","LU0572944931.SGD","LU0417516902.SGD","LU0708995583.HKD","LU0516422952.EUR","LU0359201612.USD","ESG","LU1242518931.SGD","LU1720050803.USD","LU0039217434.USD","BK4121","LU0417516738.SGD","LU0823426308.USD","BK1141","SG9999002463.SGD","LU0856984785.SGD","LU0327786744.USD","LU0348735423.USD","LU0326950275.SGD","LU0823426480.USD","LU0516423174.USD","LU0588546209.SGD","IE00B0JY6N72.USD","LU0979878070.USD","LU0320764599.SGD","LU0052750758.USD","LU0819121731.USD","LU1688375341.USD","02269","LU2039709279.SGD","LU0359202008.SGD","SG9999002562.SGD","LU0307460666.USD","BK1610","LU0516422366.SGD","LU0456827905.SGD","LU0516422440.USD","BK1576","LU0456846285.SGD","WXXWY","BK1521","LU0181495838.USD"],"gpt_icon":1},{"id":"2514114718","title":"药明康德盘中异动 早盘股价大跌3.00%报61.400港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514114718","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514114718?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 10:20","pubTimestamp":1740622808,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘10时20分，药明康德股票出现波动，股价急速跳水3.00%。截至发稿，该股报61.400港元/股，成交量248.313万股，换手率0.64%，振幅4.66%。资金方面，该股资金流入5416.03万港元，流出7763.92万港元。最近的财报数据显示，该股实现营业收入307.19亿港元，净利润72.44亿港元，每股收益2.50港元，毛利123.07亿港元，市盈率15.03倍。药明康德股票所在的生物技术行业中，整体跌幅为0.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271020099631e4a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502271020099631e4a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320764599.SGD","LU2125910500.SGD","LU1046422090.SGD","02359","LU2045819591.USD","LU2242644610.SGD","LU0708995583.HKD","BK1576","LU0052750758.USD","BK1583","BK1141"],"gpt_icon":0},{"id":"2514814553","title":"艾美疫苗获FDA批准开展mRNA疫苗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814553","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514814553?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 10:12","pubTimestamp":1740622362,"startTime":"0","endTime":"0","summary":"2月27日，艾美疫苗（06660）发布公告，宣布其mRNA呼吸道合胞病毒疫苗已获得美国食品和药品监督管理局（FDA）批准开展临床试验。这是公司首次获得FDA批准进行临床试验，标志着其国际化战略的重要进展。公告中提到，该疫苗在临床前动物试验中，特异性IgG抗体滴度、真病毒中和抗体效价以及特异性T细胞免疫均显著高于国际上市的对照疫苗，显示出其研发成果的竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502273331295532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06660","BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2514819415","title":"昭衍新药盘中异动 早盘股价大涨5.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819415?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 09:51","pubTimestamp":1740621062,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时51分，昭衍新药股票出现异动，股价急速拉升5.37%。截至发稿，该股报16.100港元/股，成交量108.034万股，换手率0.91%，振幅9.55%。资金方面，该股资金流入925.19万港元，流出552.206万港元。昭衍新药股票所在的生物技术行业中，整体跌幅为0.42%。其相关个股中，北海康成-B、科济药业-B、创胜集团-B涨幅较大，振幅较大的相关个股有北海康成-B、科济药业-B、永泰生物-B，振幅分别为58.68%、18.33%、16.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227095102a25592b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227095102a25592b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","06127"],"gpt_icon":0},{"id":"2514819453","title":"维亚生物盘中异动 大幅拉升5.04%报1.460港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819453","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819453?lang=zh_cn&edition=fundamental","pubTime":"2025-02-27 09:47","pubTimestamp":1740620824,"startTime":"0","endTime":"0","summary":"2025年02月27日早盘09时47分，维亚生物股票出现波动，股价急速上涨5.04%。截至发稿，该股报1.460港元/股，成交量35.8万股，换手率0.02%，振幅4.32%。资金方面，该股资金流入43.56万港元，流出5.179万港元。维亚生物股票所在的生物技术行业中，整体跌幅为0.87%。其相关个股中，北海康成-B、科笛-B、永泰生物-B涨幅较大，振幅较大的相关个股有北海康成-B、永泰生物-B、思路迪医药股份，振幅分别为58.68%、16.25%、15.56%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094704abde871a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227094704abde871a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","01873"],"gpt_icon":0},{"id":"2514883101","title":"三重buff叠加，医疗ETF（512170）尾盘溢价飙升！CXO强劲反弹，药明康德涨超3%！AI医疗再调整，迪安诊断领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2514883101","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514883101?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 20:01","pubTimestamp":1740571260,"startTime":"0","endTime":"0","summary":"经过连续2日的调整，2月26日，CXO助力医疗板块回暖，中证医疗指数震荡收涨。CXO概念股强劲反弹，昭衍新药、泰格医药联袂涨超4%，巨头药明康德大涨3.12%。　　此前显著受益AI医疗行情的热股继续回调，迪安诊断、卫宁健康跌幅均超4%，华大基因、华大智造跌超3%，金域医学、美年健康、联影医疗跌逾1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-02-26/doc-inemvnmf7262642.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2125910500.SGD","LU1997245094.SGD","159891","BK0216","LU0052750758.USD","BK0070","BK0146","LU0708995583.HKD","CXO","LU2045819591.USD","603259","LU2242644610.SGD","BK0197","300244","BK1141","BK1583","LU1046422090.SGD","159828","BK0114","02359","LU1997245177.USD","BK0028","BK1576","BK0042","LU0456842615.SGD","LU2488822045.USD","BK0186","LU0320764599.SGD","BK0236","512170"],"gpt_icon":0},{"id":"2514993889","title":"康龙化成2月26日现1笔大宗交易 成交金额1123.2万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514993889","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514993889?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 17:00","pubTimestamp":1740560400,"startTime":"0","endTime":"0","summary":"　　2月26日，康龙化成收涨2.17%，收盘价为28.26元，发生1笔大宗交易，合计成交量40万股，成交金额1123.2万元。　　第1笔成交价格为28.08元，成交40.00万股，成交金额1,123.20万元，溢价率为-0.64%，买方营业部为机构专用，卖方营业部为中信证券华南股份有限公司广州万博证券营业部。　　进一步统计，近3个月内该股累计发生13笔大宗交易，合计成交金额为1.96亿元。该股近5个交易日累计上涨5.13%，主力资金合计净流入4560.49万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-02-26/doc-inemuzuz3574488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","03759","BK1141","BK0216","300759"],"gpt_icon":0},{"id":"2514230885","title":"恒瑞医药(600276.SH)：HRS-1301片获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2514230885","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514230885?lang=zh_cn&edition=fundamental","pubTime":"2025-02-26 16:46","pubTimestamp":1740559568,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于HRS-1301片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1301片是公司自主研发的1类化学药物。临床前研究显示，HRS-1301可有效改善高脂血症。目前全球范围内暂无同类药物获批上市。截至目前，HRS-1301片相关项目累计研发投入约1,836万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1254644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK0060","BK0188","BK0028","BK0196","BK1141","LU1064131003.USD","LU1328615791.USD","LU0405327148.USD","LU2148510915.USD","LU1064130708.USD","600276","LU0405327494.USD","LU1969619763.USD","03347","BK0239","BK1583","LU2328871848.SGD","BK0012","BK1576","BK0183"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":9,"totalSize":218}]}}